Boehringer kindles NASH treatments with Pharmaxis’ drug acquisition

19/05/2015 - 4 minutes

Does NASH mean anything to you? You should be vigilant about this market as it could be the source of next major blockbusters. This new and latest acquisition by Boehringer, is yet another sign of the growing interest for NASH treatments, already chased by companies such as Intercept, Genfit or Gilead.

NASH, or non-alcoholic steatohepatitis, is regarded as a major cause of fibrosis and cirrhosis of the liver and is an area of high unmet clinical need. The high prevalence of type 2 diabetes and obesity, which can lead to NASH, is considered to make NASH one of the most common causes of advanced liver disorders in the coming decades.  The market has been estimated to exceed €3Bn by 2025, arousing the envy of Big Pharma companies and mid-size Biotechs.

Just two months after getting an option to buy Australian Pharmaxis’ NASH drug, Boehringer Ingelheim has decided to entirely pocket the program. Pharmaxis‘ investigational drug candidate PXS4728A is an inhibitor of the vascular adhesion protein-1 that works by blocking leucocyte adhesion and tissue infiltration in inflammatory processes.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member